A new study describes a novel approach for developing new antibiotics. The researchers developed a structure-guided design to create prodrugs that act as a "Trojan Horse," allowing antibiotics to reach resistant bacteria. The work paves the way for structure-guided development of S. aureus-specific prodrugs and establishes a pipeline for the identification of additional prodrug activating enzymes.
Acceleron's lead therapeutic candidate, sotatercept, is a reverse-remodeling agent designed to rebalance TGF-beta superfamily signaling. Sotatercept is in Phase III studies as an add-on to current standard of care for the treatment of PAH, as well as in a Phase II trial in patients with combined post- and pre-capillary pulmonary hypertension in heart failure with preserved ejection fraction. Sotatercept met its primary endpoint of improvement in pulmonary vascular resistance in PAH patients in an earlier Phase II trial.
Lead anti-inflammatory candidate PA401 stops native IL-8 from glycan binding and neutrophil activation.
Since the beginning of March, Applikon Biotechnology has been working with the Laboratory of Virology and the Bioprocess Engineering Group of Wageningen University on the development of a COVID-19 vaccine, based on mimicking the virus’s “spike protein.
iThemba Pharmaceuticals' service division and Pyxis Discovery signed a collaborative agreement to jointly market each other’s services. Pyxis' computational chemistry and lead discovery expertise...
City of Hope scientists have identified and developed two potent small molecules that appear to suppress tumor growth in multiple cancers even when other treatments cease to work, possibly due to the development of drug resistance. Their study provides new insight into how cancer stem cells replenish and visibility into how cancer evades our immune system.
Researchers have developed a machine learning method to support the time-intensive and resource-demanding process of optimizing antibody therapeutics. The method predicts antigen specificity from antibody sequence via deep learning. In this study, the researchers provide a proof of concept for their new method using Roche's antibody cancer drug Herceptin. Now, they are applying their AI method to optimize antibody drugs that are in clinical development.
The collaboration comes as the FDA is reviewing an NDA for infigratinib in patients with previously treated, FGFR-mutant cholangiocarcinoma (bile duct cancer).
Companies agree to commercialize targeted anti-cancer treatments for up to two undisclosed targets
Researchers developed a new genetic platform that allows efficient production of naturally occurring molecules and used it to produce a novel antibiotic compound.